Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
1 clinical trials · Condition
◉ Watch Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
| Record | Firm | Date |
|---|---|---|
| A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma (NCT07682272) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2026-07-01 |
Track Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk automatically
Every clearance here is in the API, with alerts when new ones post.